AbbVie (ABBV) Free Cash Flow (2012 - 2026)
AbbVie (ABBV) posted quarterly Free Cash Flow of $3.6 billion for Q1 2026, up 154.57% year-over-year from $1.4 billion in Q1 2025, and down 27.1% quarter-over-quarter from $4.9 billion in Q4 2025.
AbbVie (ABBV) Free Cash Flow (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Free Cash Flow for 15 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 154.57% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $20.0 billion (up 29.87% YoY), while the FY2025 annual figure was $17.8 billion, changed 0.09% from the prior year.
- Free Cash Flow retreated to $3.6 billion in Q1 2026 per ABBV's latest filing, from $4.9 billion in the prior quarter.
- Across five years, Free Cash Flow topped out at $7.4 billion in Q3 2022 and bottomed at $1.4 billion in Q1 2025.
- Historically, Free Cash Flow has averaged $5.0 billion across 5 years, with a median of $4.9 billion in 2025.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 66.94% — and 2026, when it soared 154.57%.
- AbbVie's Free Cash Flow stood at $7.2 billion in 2022, then sank by 36.96% to $4.5 billion in 2023, then jumped by 48.57% to $6.8 billion in 2024, then dropped by 27.65% to $4.9 billion in 2025, then dropped by 27.1% to $3.6 billion in 2026.
- Business Quant data shows ABBV's Free Cash Flow at $3.6 billion in Q1 2026, $4.9 billion in Q4 2025, and $6.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.11 Bn |
| Jun 30, 2026 | 3.11 Bn |
| Mar 31, 2026 | 3.56 Bn |
| Mar 31, 2026 | 3.56 Bn |
| Dec 31, 2025 | 4.89 Bn |
| Dec 31, 2025 | 4.89 Bn |
| Sep 30, 2025 | 6.64 Bn |
| Sep 30, 2025 | 6.64 Bn |
| Jun 30, 2025 | 4.88 Bn |
| Jun 30, 2025 | 4.88 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Dec 31, 2024 | 6.76 Bn |
| Dec 31, 2024 | 6.76 Bn |
| Sep 30, 2024 | 5.20 Bn |
| Sep 30, 2024 | 5.20 Bn |
| Jun 30, 2024 | 2.03 Bn |
| Jun 30, 2024 | 2.03 Bn |
| Mar 31, 2024 | 3.85 Bn |
| Mar 31, 2024 | 3.85 Bn |